Stunning news to anyone without a brain: industry funding affects research. 
Pharmaceutical giant Eli Lilly and Co. recently funded five studies that
compared its antipsychotic drug Zyprexa with Risperdal, a competing drug
made by Janssen. All five showed Zyprexa was superior in treating
schizophrenia.But when Janssen sponsored its own studies comparing the two drugs,
Risperdal came out ahead in three out of four.In fact, when psychiatrist John Davis analyzed every publicly available
trial funded by the pharmaceutical industry pitting five new
antipsychotic drugs against one another, nine in 10 showed that the best
drug was the one made by the company funding the study.“On the basis of these contrasting findings in head-to-head trials, it
appears that whichever company sponsors the trial produces the better
antipsychotic drug,” Davis and others wrote in the American Journal of
Psychiatry.